JADPRO Roundtable Series: Best Practices in the Use of BTK Inhibitors in CLL

Best Practices in the Use of BTK Inhibitors in CLL

JNCCN Spotlights

Obinutuzumab

Zanubrutinib

Update Venetoclax in CLL

Acalabrutinib

Resources

For your Patients

Leukemia & Lymphoma Society

NCCN COVID-19 Resources Page

Cancer.gov

Patient Power

Sections

JNCCN Spotlights
Videos
News
Medical Literature
CE Activities
Clinical Trials
For Your Patients

360 Hub

About
Contact
Disclaimer
Disclosures
Privacy Policy
Terms of Use

NCCN Resources

NCCN Guidelines^®
NCCN Compendium^®
NCCN Templates^®
NCCN Guidelines for Patients^®
JNCCN

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.

Site Editor

JADPRO Roundtable Series: Best Practices in the Use of BTK Inhibitors in CLL